Price$0.43-0.14 (-25.11%)
2026-07-162026-10-16
News · 26 weeks40+100%
2026-04-192026-10-11
Mix2190d
- Insider9(43%)
- Other5(24%)
- SEC Filings4(19%)
- Earnings1(5%)
- Offering1(5%)
- Analyst1(5%)
Latest news
25 items- PRHeartBeam Joins European EXIT-CVD Research Consortium to Advance At-Home ECG Monitoring for Early Detection of Acute Coronary Syndrome (ACS) in High-Risk PatientsHeartBeam joins Philips, Medtronic, GE HealthCare and other global healthcare leaders in the EU-funded EXIT-CVD research consortium HeartBeam will lead the HEART-CHECK Study, one of the project’s 22 studies HEART-CHECK will evaluate whether HeartBeam’s at-home 3D ECG can help clinicians recognize recurrent events earlier in patients recently discharged after ACS HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced it is a contributing partner in the launch of the EXIT-CVD research project, co-funded by the European Union Innovative Health Initiative (IHI) and industry partners. The
- INSIDERSEC Form 4 filed by Heartbeam Inc.4 - HeartBeam, Inc. (0001779372) (Issuer)
- INSIDERSEC Form 4 filed by Heartbeam Inc.4 - HeartBeam, Inc. (0001779372) (Issuer)
- INSIDERSEC Form 4 filed by Heartbeam Inc.4 - HeartBeam, Inc. (0001779372) (Issuer)
- INSIDERSEC Form 4 filed by Heartbeam Inc.4 - HeartBeam, Inc. (0001779372) (Issuer)
- INSIDERSEC Form 4 filed by Heartbeam Inc.4 - HeartBeam, Inc. (0001779372) (Issuer)
- INSIDERSEC Form 4 filed by Heartbeam Inc.4 - HeartBeam, Inc. (0001779372) (Issuer)
- PRCommercial Orders, FDA Firepower and Crypto MomentumDENVER, Oct. 05, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Today’s headlines include Kraig Biocraft Laboratories (OTCQB:KBLB), HeartBeam (NASDAQ:BEAT), QTREX Quantum (NASDAQ:QTEX), and Veea Inc. (NASDAQ:VEEA). Kraig Biocraft Laboratories: Spider Silk Enters Commercial Arena Kraig Biocraft Laboratories (OTCQB:KBLB) is moving into one of the most important phases of its long-running spider-silk story: commercial customer validation. On September 29, the company announced the shipment of its first commercial order of recombinant spider silk yarn to a globally recognized performance sports brand. The custom-engineered yarn is part of a confidential pilot-development program targeting pe
- PRHeartBeam Receives FDA Breakthrough Device Designation for Heart Attack AssessmentDesignation recognizes the potential of HeartBeam’s 3D ECG technology to help physicians assess suspected heart attacks outside the hospitalBreakthrough status provides prioritized FDA interaction as HeartBeam advances toward a pivotal studyDesignation positions HeartBeam to pursue an expedited Medicare coverage pathwayUpdates on ALIGN-ACS data at TCT and the HEADSTART-ACS study expected in coming weeksHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the HeartBeam System as a tool for assessing
- ANALYSTHeartBeam downgraded by H.C. WainwrightH.C. Wainwright downgraded HeartBeam from Buy to Neutral
- PRHeartBeam, Inc. Letter to ShareholdersHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today issued a letter to shareholders from its Executive Chairman Richard Ferrari, and President and Founder, Branislav Vajdic, PhD. Dear Fellow Shareholders, HeartBeam is at an inflection point, and we want to be direct about what we are doing, what we are not doing, and why. We have learned a great deal from the early commercialization of our FDA-cleared arrhythmia product. The most important lesson is that scaling commercialization ourselves would require substantial capital and commercial infrastructure at a time when we believe those resources c
- SECHeartbeam Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - HeartBeam, Inc. (0001779372) (Filer)
- SECSEC Form 424B5 filed by Heartbeam Inc.424B5 - HeartBeam, Inc. (0001779372) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Heartbeam Inc.SCHEDULE 13D/A - HeartBeam, Inc. (0001779372) (Subject)
- SECSEC Form 10-Q filed by Heartbeam Inc.10-Q - HeartBeam, Inc. (0001779372) (Filer)
- PRHeartBeam Reports Second Quarter 2026 ResultsCompleted Enrollment in ALIGN-ACS Heart Attack Detection Pilot Study Ahead of Schedule; Full Results to be Presented at TCT 2026 Surpassed 50% Enrollment Ahead of Schedule in Indonesian Government-Supported HEADSTART-ACS Pilot Study for Heart Attack Detection Initial Commercial Launch of the HeartBeam System Underway with Multiple Signed Agreements Across Four Targeted U.S. Geographies Completed Working Prototype of 12-Lead ECG Extended Wear Patch Targeting the $2 Billion Ambulatory Cardiac Monitoring Market Lowered Expected Full Year 2026 Net Operating Cash Outflow to Below $14.0 Million Management to Host Webcast and Conference Call Today at 4:30 p.m. ET HeartBeam, Inc.
- SECHeartbeam Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - HeartBeam, Inc. (0001779372) (Filer)
- PRHeartBeam to Host Second Quarter 2026 Results Conference Call on Thursday, August 13, 2026 at 4:30 p.m. Eastern TimeHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, August 13, 2026 at 4:30 p.m. Eastern time to discuss its results for the second quarter ended June 30, 2026, and will be providing updates on its strategy to accelerate global adoption of its ambulatory ECG signal platform. A press release detailing these results will be issued prior to the call. HeartBeam Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank will host the conference call, followed by a question-and-answer period. The c
- INSIDERChief Technology Officer Persen Kenneth Harry was granted 105,740 shares, increasing direct ownership by 31% to 448,290 units (SEC Form 4)4 - HeartBeam, Inc. (0001779372) (Issuer)
- INSIDERCFO Cruickshank Tim was granted 167,760 shares, increasing direct ownership by 232% to 239,990 units (SEC Form 4)4 - HeartBeam, Inc. (0001779372) (Issuer)
- INSIDERPresident Vajdic Branislav was granted 3,060,870 shares, increasing direct ownership by 336% to 3,970,784 units (SEC Form 4)4 - HeartBeam, Inc. (0001779372) (Issuer)
- ANALYSTMaxim Group initiated coverage on HeartBeam with a new price targetMaxim Group initiated coverage of HeartBeam with a rating of Buy and set a new price target of $2.00
- PRHeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG DevicePatent extends HeartBeam's ECG hardware platform with multi-modal sensing capabilities Acoustic sensors enable HeartBeam’s device to function as a "digital stethoscope" to assess heart valve function Thoracic impedance capability opens the door to heart failure monitoring without a surgical procedure HeartBeam now holds 26 issued patents worldwide, reflecting continued investment in building a durable IP moat around its platform HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the allowance of a new U.S. patent that significantly expands the capabilities of its credit card-si
- SECHeartbeam Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - HeartBeam, Inc. (0001779372) (Filer)
- PRHeartBeam Completes Enrollment in Heart Attack Detection Pilot Study Ahead of ScheduleAccelerated enrollment completion in ALIGN-ASS study underscores HeartBeam’s execution on its key strategic priority of heart attack detectionData analysis is underway, with full results anticipated for presentation at upcoming cardiology conferenceFindings will inform the design of the planned U.S. pivotal study and support the FDA pathwayFuture indication expansion could unlock a large addressable market of millions of patients at riskHeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care through powerful cardiac insights, today announced completion of patient enrollment in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack
BEAT FAQ
7 questionsWhat does Heartbeam Inc. do?
HeartBeam, Inc., a medical technology company, primarily focusing on telemedicine solutions that enable the detection and monitoring of cardiac disease. It focuses on providing diagnostic data to help physicians with care management of patients with cardiovascular disease. The company is developing its telehealth product that comprises a credit card sized electrocardiograms machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is based in Santa Clara, California.Where does BEAT stock trade?
Heartbeam Inc. (BEAT) is listed on NASDAQ.What sector and industry is BEAT in?
Heartbeam Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did Heartbeam Inc. go public?
Heartbeam Inc. (BEAT) completed its IPO in 2021.What are analysts saying about BEAT?
Heartbeam Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-09-22. Recent price targets range from $200.00 to $800.00.What companies are similar to BEAT?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare BEAT side-by-side with any of them on Quantisnow.How can I track BEAT on Quantisnow?
Quantisnow aggregates Heartbeam Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BEAT to receive live email and push alerts on every new disclosure.